# A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)

> **NCT04945460** · PHASE2 · COMPLETED · sponsor: **Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA** · enrollment: 164 (actual)

## Conditions studied

- Hypertension, Pulmonary

## Interventions

- **DRUG:** Sotatercept 0.3 mg/kg
- **DRUG:** Placebo
- **DRUG:** Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg

## Key facts

- **NCT ID:** NCT04945460
- **Lead sponsor:** Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-29
- **Primary completion:** 2025-09-05
- **Final completion:** 2026-04-09
- **Target enrollment:** 164 (ACTUAL)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04945460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04945460, "A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT04945460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*